Respiratory syncytial virus, or RSV, is a common seasonal virus that affects the airways of the lungs. Many people know RSV as a virus that causes problems for infants, but it can also cause serious complications including inflammation of the lungs and pneumonia in older adults.
Tulane University’s Clinical Translation Unit (CTU) is part of the EVERGREEN Study, which is testing the efficacy of a vaccine developed by Janssen Vaccines & Prevention B.V. The study is examining if the vaccine can prevent RSV in seniors.
People 65 years of age and older are eligible to participate in the EVERGREEN Study if they don’t have serious health conditions and are able to use smartphones, tablets and/or computers. The EVERGREEN Study will last for up to 2 RSV seasons, which usually begin in early fall and end in early spring. Qualified participants may receive the study vaccine and some study-related medical care at no cost along with reimbursement for their study-related travel costs and efforts.
To learn more about the EVERGREEN Study and see if you qualify, visit evergreentrial.com or call the Tulane CTU at (504) 988-9801.